SPOTLIGHT: Sepracor licenses epilepsy drug rights


Sepracor is shelling out $75 million up front to license the marketing rights for an experimental epilepsy drug from Portugal's Bial. Sepracor will pay up to $100 million more in developmental and regulatory milestones. Release

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.